Lineage Cell Therapeutics, Inc.
LCTX
$0.485
-$0.015-3.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.36% | 203.29% | -56.34% | -39.48% | 9.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.36% | 203.29% | -56.34% | -39.48% | 9.03% |
| Cost of Revenue | -14.06% | -17.93% | -27.20% | -27.79% | 3,980.39% |
| Gross Profit | 65.81% | 121.40% | -94.06% | 13.24% | -214.40% |
| SG&A Expenses | 480.61% | 9.13% | 2.68% | 5.78% | -82.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.15% | -4.18% | -11.81% | -10.22% | -42.48% |
| Operating Income | -80.44% | 42.73% | -16.78% | -0.29% | 57.34% |
| Income Before Tax | 31.06% | 58.07% | -10.96% | -5.65% | 25.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.06% | 58.07% | -10.96% | -48.91% | 25.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 62.30% | -168.75% | 150.00% | -50.00% | -862.50% |
| Net Income | 31.46% | 57.33% | -10.15% | -49.63% | 24.85% |
| EBIT | -80.44% | 42.73% | -16.78% | -0.29% | 57.34% |
| EBITDA | -86.64% | 43.35% | -17.94% | -0.23% | 58.91% |
| EPS Basic | 50.18% | 60.44% | 0.65% | -39.30% | 27.01% |
| Normalized Basic EPS | -86.96% | 59.76% | -1.60% | 8.61% | 78.50% |
| EPS Diluted | 50.18% | 60.44% | 0.65% | -39.30% | 27.01% |
| Normalized Diluted EPS | -86.96% | 59.76% | -1.60% | 8.61% | 78.50% |
| Average Basic Shares Outstanding | 37.24% | 7.99% | 10.68% | 7.51% | 2.95% |
| Average Diluted Shares Outstanding | 37.24% | 7.99% | 10.68% | 7.51% | 2.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
